Access Pharmaceuticals Inc.
Access Pharmaceuticals Inc. is listed today as Abeona Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2015 | $14 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| May 2015 | $10 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Oct 2012 | $10 M | No. 2 | $10 to $50 million | equity | SEC | |
| Nov 2011 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Abeona Therapeutics Inc., its revenue in fiscal 2025 came from these product and service lines: License $3.40 million (58%).
Annual report (SEC XBRL) · Dec 2025
Access Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2015).
SEC Form D · Jun 2015
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2015
Products and services#
No products or services of Access Pharmaceuticals Inc. are on record.
Investors#
No investor of Access Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.
Largest shareholders today
Institutions holding Abeona Therapeutics Inc. shares, as of Sep 30, 2026.
- Nantahala Capital Management, LLC$28 M9.47%
- Cable Car Capital, LP$19 M6.30%
- BlackRock, Inc.$18 M5.91%
- Rubric Capital Management LP$18 M5.84%
- AIGH Capital Management LLC$15 M5.07%
- Vanguard Capital Management LLC$11 M3.74%
- J. Goldman & Co LP$8 M2.65%
- AWM Investment Company, Inc.$8 M2.60%
- Kennedy Capital Management LLC$7 M2.33%
- Geode Capital Management, LLC$7 M2.32%
- Goldman Sachs Group Inc$6 M2.03%
- State Street Corp$6 M1.84%
- Propel Bio Management, LLC$5 M1.67%
- Citigroup Inc$5 M1.53%
- Bank Of America Corp /de/$4 M1.28%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Stephen B. Thompson | Mr. Thompson is the Vice President - Finance, Treasurer and Secretary of the Issuer. | Jun 2015 |
| Steven H. Rouhandeh | Mr. Rouhandeh is the Executive Chairman of the Issuer. | Jun 2015 |
| Tim B. Miller | Dr. Miller is the President and Chief Executive Officer of the Issuer. | Jun 2015 |
| Jeffrey B. Davis | Executive officer | Nov 2012 |
| Jeffrey H. Davis | Director | Jun 2015 |
| Mark J. Ahn | Director | Jun 2015 |
| Mark J. Alvino | Director | Jun 2015 |
| Stephen B. Howell | Director | Jun 2015 |
| Tim B. Miller | Dr. Miller is the President and Chief Executive Officer of the Issuer. | Jun 2015 |
| Todd B. Wider | Director | Jun 2015 |
| Todd B. Widder | Director | May 2015 |
| mark J. Alvino | Director | May 2015 |
| Jeffrey B. Davis | Director | Nov 2012 |
| Mark J. Ahn, Ph.D. | Director | Nov 2012 |
| Stephen B. Howell, M.D. | Director | Nov 2012 |
| Steven H. Rouhandeh | Director | Nov 2012 |
| Esteban H. Cvitkovic, M.D. | Vice Chairman - Europe | Nov 2011 |
| Stephen B. Thompson | Promoter | Nov 2012 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.